Depomed Gets Patent Win Over Generic Nucynta Drugmakers

Depomed Inc. won a major ruling when a New Jersey federal judge said patents relating to its painkiller drug Nucynta are valid and that several generic drugmakers have infringed claims on the patents, giving the pharmaceutical giant a market lock on Nucynta products through 2025.

Rate this item
(0 votes)
Login to post comments

Newsletter Subscription

Joomla forms builder by JoomlaShine

IP2017 Banner 380x280

IP Era 300x250

Go to top